CJC-1295 + Ipamorelin: What’s In the Blend and the Research on Each Component

What is the CJC-1295 + Ipamorelin blend?

The catalogue lists “CJC-1295 + Ipamorelin” as a co-formulated research preparation — for example a 5+5 mg blend, alongside a combined 20 mg listing. That is a naming and composition fact: the label records that two sequences, CJC-1295 and Ipamorelin, are supplied together.

One thing is worth stating at the outset, because it is the single most common point of confusion about this pairing: the two are studied at different receptors. This page therefore treats them as two separate research questions that happen to be supplied in one vial — not as a single mechanism, and not as a combined regimen. The rest of the page summarises each component briefly, hands off to its full research page, and states plainly what the literature does and does not say about the two together.

The two components

CJC-1295 (a GHRH analog)

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone, built on the first 29 residues of human GHRH — the GRF(1-29) fragment — with stabilising substitutions. Its literature draws a clear molecule distinction between the DAC (Drug Affinity Complex, albumin-binding) form and the no-DAC form (mod-GRF 1-29), and it acts at the GHRH receptor. Unusually for a research peptide, CJC-1295 has published human pharmacokinetic and pharmacodynamic trials (Teichman et al., 2006; Ionescu & Frohman, 2006) that measured plasma GH and IGF-1 as markers. For the full detail, see CJC-1295 research: GHRH-analog mechanism. Those GH and IGF-1 values are what the studies measured, not an effect in a reader.

Ipamorelin (a selective GH secretagogue)

Ipamorelin is a synthetic pentapeptide, first described by Raun et al. (1998) as “the first selective growth hormone secretagogue.” It acts as an agonist at the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) — a different receptor from CJC-1295’s. Its evidence base is largely preclinical, with a single small phase-2 human trial in a gastrointestinal-motility indication (Beck et al., 2014) whose primary efficacy endpoint was not met. For the full detail, see Ipamorelin research: ghrelin-receptor mechanism.

Two different receptors — a mechanism contrast

Because vendor pages routinely blur the two together, the distinction is worth stating in plain terms: CJC-1295 acts at the GHRH receptor, while Ipamorelin acts at the ghrelin / GHS-R1a receptor. They are different molecules, at different receptors, studied as separate questions in the published literature. This section exists to correct that common conflation — it is a mechanistic distinction, not a rationale to combine the two, and nothing here should be read as a claim that using both does more than either on its own.

Is there research on the combination itself?

Stated plainly, because it is the point that matters most: the published literature studies CJC-1295 and Ipamorelin separately. There is essentially no dedicated, peer-reviewed research on the two administered as a single combination — no controlled study establishing what the pairing does as a unit, and none comparing the blend against either peptide on its own.

Combining the two sequences into one research preparation is therefore a formulation and catalogue decision, not a finding. This page makes no claim that the two do anything together. The two component pages above are the actual evidence base; read the blend as a packaging fact and those pages as the research.

It is worth being explicit about why the honest answer is “essentially none” rather than simply “not summarised here.” Peer-reviewed research is built around single, defined molecules studied in isolation, so that any observed change can be attributed to one compound; a co-formulated blend is instead assembled at the catalogue stage. A study of CJC-1295 and Ipamorelin given together would be a separate piece of work with its own design and controls, and no such study exists in a form this page could responsibly cite. That the two act on different receptors is a reason the literature has kept them apart as separate questions — not a reason, on this page, to present them as a single one. The most accurate statement is the one the two component summaries already make: each has its own distinct record, and the pairing adds no shared evidence base of its own.

Blend vs the components — a formulation fact

The catalogue lists the pairing as a co-formulated blend, along with a combined-milligram listing. That is a packaging and formulation description — one vial containing both sequences — and an identity fact, not a protocol or a ratio presented as a regimen. The milligram figure on the label is a catalogue quantity that identifies the material, not a dose, and this page gives no per-use amount, timing, or administration detail.

Research-grade sourcing and verification

For laboratory research use only, the CJC-1295 + Ipamorelin preparation is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation. For a two-peptide preparation, per-sequence identity confirmation is the whole assurance. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. Sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799–805. PMID 16352683. (CJC-1295 component.)
2. Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab. 2006;91(12):4792–4797. PMID 17018654. (CJC-1295 component.)
3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998;139(5):552–561. PMID 9849822. (Ipamorelin component.)
4. Beck DE, Sweeney WB, McCarter MD. “Proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” International Journal of Colorectal Disease. 2014;29(12):1527–1534. PMID 25331030. (Ipamorelin component; primary endpoint not met.)